![]() ![]() Although effects on humans were identified human data were not suitable due to the lack of dose–response data from which a dose without effect could be identified. ![]() ![]() The Panel assessed the suitability of human data to be used for the derivation of a health-based guidance value. From a neurodevelopmental toxicity study, a no observed adverse effect level (NOAEL) of 3,200 mg monosodium glutamate/kg body weight (bw) per day could be identified. The Panel considered that glutamic acid–glutamates (E 620–625) did not raise concern with regards to genotoxicity. The only effect observed was increased kidney weight and increased spleen weight however, the increase in organ weight was not accompanied by adverse histopathological findings and, therefore, the increase in organ weight was not considered as an adverse effect. No adverse effects were observed in the available short-term, subchronic, chronic, reproductive and developmental studies. Glutamate is absorbed in the intestine and it is presystemically metabolised in the gut wall. The EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS) provides a scientific opinion re-evaluating the safety of glutamic acid–glutamates (E 620–625) when used as food additives. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |